Cargando…

Use of Nafamostat Mesilate as an Anticoagulant during Extracorporeal Membrane Oxygenation

Although the incidence of bleeding complications during extracorporeal membrane oxygenator (ECMO) support has decreased in various trials, bleeding is still the most fatal complication. We investigated the ideal dosage and efficacy of nafamostat mesilate for use with ECMO in patients with acute card...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Sang Jin, Kim, Hyoung Soo, Kim, Kun Il, Whang, Sung Mi, Hong, Kyung Soon, Lee, Won Ki, Lee, Sun Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Academy of Medical Sciences 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3124727/ https://www.ncbi.nlm.nih.gov/pubmed/21738350 http://dx.doi.org/10.3346/jkms.2011.26.7.945

Ejemplares similares

The role of nafamostat mesilate as a regional anticoagulant during extracorporeal membrane oxygenation
por: Lee, Jae Ha, et al.
Publicado: (2022)

Validation of Nafamostat Mesilate as an Anticoagulant in Extracorporeal Membrane Oxygenation: A Large-Animal Experiment
por: Han, Sung Joon, et al.
Publicado: (2018)

Utility and safety of nafamostat mesilate for anticoagulation in dogs
por: Isayama, Noriko, et al.
Publicado: (2022)

Cardiac arrest caused by nafamostat mesilate
por: Kim, Hyo Shik, et al.
Publicado: (2016)

The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
por: Kim, Joo Seong, et al.
Publicado: (2022)

Comparison between nafamostat mesilate and unfractionated heparin as anticoagulant during continuous renal replacement therapy
por: Makino, S, et al.
Publicado: (2015)

Nafamostat Mesilate as an Anticoagulant During Continuous Renal Replacement Therapy in Patients With High Bleeding Risk: A Randomized Clinical Trial
por: Choi, Ji-Young, et al.
Publicado: (2015)

Nafamostat Mesilate Inhibits TNF-α-Induced Vascular Endothelial Cell Dysfunction by Inhibiting Reactive Oxygen Species Production
por: Kang, Min-Woong, et al.
Publicado: (2015)

Cardiac arrest caused by nafamostat mesilate: Kounis syndrome in the dialysis room?
por: Koniari, Ioanna, et al.
Publicado: (2017)

Successful Nafamostat Mesilate Administration for Andexanet Alfa-Induced Heparin Resistance
por: Kitaura, Atsuhiro, et al.
Publicado: (2023)

Nafamostat mesilate promotes endothelium-dependent vasorelaxation via the Akt-eNOS dependent pathway
por: Choi, Sujeong, et al.
Publicado: (2016)

Phase II trial of nafamostat mesilate/gemcitabin/S-1 for unresectable pancreatic cancer
por: Uwagawa, Tadashi, et al.
Publicado: (2022)

Nafamostat Mesilate: Can It Be Used as a Conduit Preserving Agent in Coronary Artery Bypass Surgery?
por: Yoon, Yoo Sang, et al.
Publicado: (2013)

Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis
por: Lin, Yao, et al.
Publicado: (2022)

Nafamostat Mesilate Enhances the Radiosensitivity and Reduces the Radiation-Induced Invasive Ability of Colorectal Cancer Cells
por: Sugano, Hiroshi, et al.
Publicado: (2018)

Ability of Nafamostat Mesilate to Prolong Filter Patency during Continuous Renal Replacement Therapy in Patients at High Risk of Bleeding: A Randomized Controlled Study
por: Lee, Yong Kyu, et al.
Publicado: (2014)

The modulation of TRPM7 currents by nafamostat mesilate depends directly upon extracellular concentrations of divalent cations
por: Chen, Xuanmao, et al.
Publicado: (2010)

Extracorporeal membrane oxygenation in near-drowning patients with cardiac or pulmonary failure
por: Kim, Kun Il, et al.
Publicado: (2014)

Efficacy of Veno-Venous Extracorporeal Membrane Oxygenation in Severe Acute Respiratory Failure
por: Lee, Jae Jun, et al.
Publicado: (2015)

Nafamostat mesilate attenuates neuronal damage in a rat model of transient focal cerebral ischemia through thrombin inhibition
por: Chen, Tao, et al.
Publicado: (2014)

Nafamostat mesilate, a nuclear factor kappa B inhibitor, enhances the antitumor action of radiotherapy on gallbladder cancer cells
por: Takada, Naoki, et al.
Publicado: (2021)

Multicenter, single-blind, randomized controlled study of the efficacy and safety of favipiravir and nafamostat mesilate in patients with COVID-19 pneumonia
por: Ikeda, Mahoko, et al.
Publicado: (2023)

Outcomes of Urgent Interhospital Transportation for Extracorporeal Membrane Oxygenation Patients
por: Yang, Jun Tae, et al.
Publicado: (2022)

Population Pharmacokinetics of Meropenem in Critically Ill Korean Patients and Effects of Extracorporeal Membrane Oxygenation
por: Lee, Dong-Hwan, et al.
Publicado: (2021)

Anticoagulation on extracorporeal membrane oxygenation (ECMO)
por: Khilnani, Praveen
Publicado: (2017)

Preventing thrombosis in a COVID‐19 patient by combined therapy with nafamostat and heparin during extracorporeal membrane oxygenation
por: Doi, Shunichi, et al.
Publicado: (2020)

Population pharmacokinetics of piperacillin/tazobactam in critically ill Korean patients and the effects of extracorporeal membrane oxygenation
por: Kim, Yong Kyun, et al.
Publicado: (2022)

Glycogen synthase kinase‐3β activity plays a key role in the antitumor effect of nafamostat mesilate in pancreatic cancer cells
por: Haruki, Koichiro, et al.
Publicado: (2017)

Clinical outcomes of extracorporeal membrane oxygenation in acute traumatic lung injury: a retrospective study
por: Lee, Hong Kyu, et al.
Publicado: (2020)

Endogenous glycosaminoglycan anticoagulation in extracorporeal membrane oxygenation
por: MacLaren, Graeme, et al.
Publicado: (2014)

Nafamostat mesilate for prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis: A systematic review and meta-analysis based on prospective, randomized, and controlled trials
por: Xie, Yu, et al.
Publicado: (2023)

Anticoagulation Therapy during Extracorporeal Membrane Oxygenator Support in Pediatric Patients
por: Cho, Hwa Jin, et al.
Publicado: (2017)

Carinal Reconstruction and Sleeve Right Upper Lobectomy Assisted with Extracorporeal Membrane Oxygenator for Non-small Cell Lung Cancer - A case report -
por: Lee, Hee Sung, et al.
Publicado: (2011)

Blood Transfusion Strategies in Patients Undergoing Extracorporeal Membrane Oxygenation
por: Kim, Hyoung Soo, et al.
Publicado: (2017)

Use of argatroban in combination with nafamostat mesilate in open-heart surgery for a pediatric patient with heparin-induced thrombocytopenia type II: a case report
por: Kawamoto, Shuji, et al.
Publicado: (2020)

How to manage anticoagulation during extracorporeal membrane oxygenation
por: Levy, Jerrold H., et al.
Publicado: (2022)

Management of Anticoagulation during Extracorporeal Membrane Oxygenation in Children
por: Chegondi, Madhuradhar, et al.
Publicado: (2022)

Out-of-hospital cardiac arrest patients treated with cardiopulmonary resuscitation using extracorporeal membrane oxygenation: focus on survival rate and neurologic outcome
por: Lee, Jae Jun, et al.
Publicado: (2016)

Fatal anaphylaxis Due to Nafamostat Mesylate During Hemodialysis
por: Kim, Joo-Hee, et al.
Publicado: (2021)

Anticoagulation with direct thrombin inhibitors during extracorporeal membrane oxygenation
por: Burstein, Barry, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_2oippuk2fvgcv4g3a2nduct065